Business Context and Reporting Period
Company: Blue Water Acquisition Corp. III (BLUW)
Reporting Period: Quarter ended September 30, 2025 (Q3 2025)
Business Type: Cayman Islands exempted company (Special Purpose Acquisition Company or "SPAC") incorporated on November 1, 2024.
Status: The Company has not commenced operations. Activities are limited to formation, its Initial Public Offering (IPO) consummated on June 11, 2025, and the search for a target business combination. The Company expects to focus on biotechnology, healthcare, and technology sectors.
Key Financial Metrics
| Metric | Value (Sep 30, 2025) | Value (Dec 31, 2024) |
|---|---|---|
| Total Assets | $257,193,812 | $25,000 |
| Cash (Outside Trust) | $759,229 | $0 |
| Trust Account Balance | $256,272,459 | $0 |
| Total Liabilities | $9,146,805 | $48,541 |
| Deferred Underwriting Fee | $8,855,000 | $0 |
| Working Capital | $577,284 | ($48,541) |
| Net Income (9 Months) | $2,660,637 | N/A |
| Operating Expenses (9 Months) | $611,822 | N/A |
| Trust Account Income (9 Months) | $3,272,459 | N/A |
Material Changes vs. Prior Period
- Capitalization Event: The Company consummated its IPO on June 11, 2025, selling 25,300,000 Units (including full over-allotment) at $10.00 per unit, generating gross proceeds of $253,000,000. Simultaneously, it sold 683,000 Private Placement Units for $6,830,000.
- Trust Account Funding: $253,000,000 was deposited into the Trust Account. As of September 30, 2025, the balance grew to $256,272,459 due to interest income.
- Liabilities: Total liabilities increased from $48,541 to $9,146,805, primarily driven by the recognition of an $8,855,000 deferred underwriting fee liability.
- Equity Structure: Class A ordinary shares subject to possible redemption increased from 0 to 25,300,000 shares. Class B founder shares increased from 5,750,000 to 6,325,000 following a share capitalization.
- Profitability: The Company reported a net income of $2,660,637 for the nine months ended September 30, 2025, driven entirely by interest income on the Trust Account, offset by operating expenses of $611,822.
Outlook, Risks, and Contingencies
- Business Combination Deadline: The Company has 24 months from the IPO closing (June 11, 2025) to complete an initial business combination. If unsuccessful, it must redeem public shares and liquidate.
- Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern for one year from the issuance date due to a lack of operating revenues and reliance on the Sponsor for working capital loans.
- Internal Controls: The Company disclosed a material weakness in internal controls over financial reporting as of September 30, 2025, citing a lack of properly designed and operating controls. A remediation plan is in progress.
- Related Party Obligations: The Company pays a $10,000 monthly administrative fee to a Sponsor affiliate. The Sponsor has agreed to indemnify the Company for certain claims that could reduce Trust Account funds below $10.00 per share, though the Company has not verified the Sponsor's ability to satisfy this obligation.
- Warrant Redemption: Warrants may be redeemed if the Class A share price exceeds $18.00 for 20 trading days within a 30-day period, subject to specific conditions post-business combination.
Investor Verification Checklist
- Trust Account Yield: Verify the current interest rate environment and its impact on the Trust Account balance, which determines the redemption price for public shareholders.
- Going Concern Status: Confirm the Sponsor's commitment and ability to provide working capital loans if the Company exhausts its $759,229 in operating cash before a business combination.
- Internal Control Remediation: Monitor the progress of the remediation plan for the material weakness in internal controls to ensure future financial reporting reliability.
- Target Selection: Assess the Company's progress in identifying a target business within the biotechnology, healthcare, or technology sectors within the 24-month window.
- Deferred Fees: Note the $8,855,000 deferred underwriting fee payable only upon successful completion of a business combination, which reduces net proceeds available to the combined entity.